Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13628769 | 0.92 | SGK1 (0.59) | SGK1ALOX15ALDH1A1MEN1KMT2A | |
| SCHEMBL13628770 | 0.87 | SGK1 (0.59) | SGK1ALOX15ALDH1A1MEN1KMT2A | |
| SCHEMBL13628785 | 0.86 | SGK1 (0.56) | SGK1ALOX15ALDH1A1MEN1KMT2A | |
| SCHEMBL13628754 | 0.84 | LMNA (0.63) | SGK1ALOX15ALDH1A1MEN1KMT2A | |
| SCHEMBL13628711 | 0.82 | SGK1 (0.69) | SGK1ALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL13628784 | 0.82 | KMT2A (0.54) | SGK1ALOX15ALDH1A1MEN1KMT2A | |
| SCHEMBL13628786 | 0.82 | SGK1 (0.54) | SGK1ALOX15ALDH1A1MEN1KMT2A | |
| SCHEMBL13628767 | 0.82 | SGK1 (0.68) | SGK1ALOX15ALDH1A1KMT2ALMNA | |
| SCHEMBL13628775 | 0.81 | ALOX15 (0.54) | SGK1ALOX15ALDH1A1MEN1KMT2A | |
| SCHEMBL13628753 | 0.80 | SGK1 (0.62) | SGK1ALOX15ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619115-B2 | Ortho-substituted N'-benzylidene-(3-hydroxyphenyl)acethydrazides | MERCK PATENT GMBH (DE) | 2009-11-17 | — | — | US | disclosed |
| US-7619115-B2 | Ortho-substituted N'-benzylidene-(3-hydroxyphenyl)acethydrazides | MERCK PATENT GMBH (DE) | 2009-11-17 | — | — | US | disclosed |
| US-20080032983-A1 | Such as N'-[1-(2-ethyl-4,6-dihydroxyphenyl)meth-(E)-ylidene]-(3-hydroxyphenyl)acetohydrazide which are serum glucocoriticoid kinase inhibitors; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular and kidney diseases, fibrosis and inflammation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-02-07 | — | — | US | disclosed |
| US-20080032983-A1 | Such as N'-[1-(2-ethyl-4,6-dihydroxyphenyl)meth-(E)-ylidene]-(3-hydroxyphenyl)acetohydrazide which are serum glucocoriticoid kinase inhibitors; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular and kidney diseases, fibrosis and inflammation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032983-A1 | Such as N'-[1-(2-ethyl-4,6-dihydroxyphenyl)meth-(E)-ylidene]-(3-hydroxyphenyl)acetohydrazide which are serum glucocoriticoid kinase inhibitors; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular and kidney diseases, fibrosis and inflammation | GRK4, SGK1, SGK2 | SGK1 2/4885ALOX15 1650/4885ALDH1A1 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.